Table 2.
Disease-free survival and overall survival at 5 years for the variables analyzed
| Variables | Disease-free survival |
Overall survival |
||
|---|---|---|---|---|
| Percentage | P-value* | Percentage | P-value* | |
| Age, years | ||||
| <50 | 95.5 | Ref | 90.9 | Ref |
| 50–70 | 86 | 0.254 | 88.1 | 0.450 |
| >70 | 81.3 | 0.113 | 72.2 | 0.324 |
| FIGO stage | ||||
| Local (stage I) | 91.0 | Ref | 90.2 | Ref |
| Advanced (stages II–IV) | 52.2 | <0.001 | 48.8 | <0.001 |
| Histological type | ||||
| Endometrioid | 89.6 | Ref | – | Ref |
| Non-endometrioid | 61.9 | <0.001 | 66.7 | 0.0001 |
| Tumor grade | ||||
| G1 | 96.3 | Ref | 95.6 | Ref |
| G2 | 80.8 | <0.001 | 82.1 | 0.001 |
| G3 | 66.7 | <0.001 | 61.9 | <0.001 |
| Myometrial invasion | ||||
| No | 86.5 | Ref | 87.4 | Ref |
| Yes | 81.4 | 0.002 | 42.9 | <0.001 |
| Incomplete surgical treatment | ||||
| No | 86.5 | Ref | 87.4 | Ref |
| Yes | 81.4 | 0.002 | 42.9 | <0.001 |
| Tumor remnant >1 cm | ||||
| No | 86.2 | Ref | 85.2 | Ref |
| Yes | 40.0 | <0.001 | 20.0 | <0.001 |
| Lymph node involvement | ||||
| Negative | 88.7 | Ref | 89.8 | Ref |
| Positive | 41.7 | <0.001 | 38.5 | <0.001 |
| Not determined | 80.1 | 0.701 | 82.5 | 0.034 |
| Lymphovascular space invasion | ||||
| Negative | 88.9 | Ref | 89.3 | Ref |
| Focal | – | – | 66.7 | 0.353 |
| Frank | 41.7 | <0.001 | 50.0 | <0.001 |
| Surgical approach | ||||
| Laparotomy | 80.0 | Ref | 80.2 | Ref |
| Laparoscopy | 87.7 | 0.110 | 87.2 | 0.153 |
| Pelvic/Para-aortic lymphadenectomy | ||||
| No | 88.7 | Ref | 82.5 | Ref |
| Yes | 82.6 | 0.233 | 85.3 | 0.340 |
| Risk group for recurrence | ||||
| Low | 95.9 | Ref | 95.2 | Ref |
| Intermediate | 87.7 | <0.001 | 83.1 | 0.003 |
| High | 62.0 | <0.001 | 62.5 | 0.0016 |
Note:
*
Log-rank test.
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; ref, reference category.